BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1010 related articles for article (PubMed ID: 10566736)

  • 1. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
    Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
    Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinom.
    Han AR; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Hepatogastroenterology; 2009; 56(93):1111-6. PubMed ID: 19760952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography.
    Verhoef C; Valkema R; de Man RA; Krenning EP; Yzermans JN
    Liver; 2002 Feb; 22(1):51-6. PubMed ID: 11906619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection.
    Schröder O; Trojan J; Zeuzem S; Baum RP
    Nuklearmedizin; 1998; 37(8):279-85. PubMed ID: 9868710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence.
    Chen YK; Hsieh DS; Liao CS; Bai CH; Su CT; Shen YY; Hsieh JF; Liao AC; Kao CH
    Anticancer Res; 2005; 25(6C):4719-25. PubMed ID: 16334166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
    Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
    J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
    Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
    Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
    Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein].
    Shang JB; Li YH; Liu FY; Zeng QL; Wang JY; He XF; Chen Y
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jun; 24(6):697-9. PubMed ID: 15201094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma.
    Cho E; Jun CH; Kim BS; Son DJ; Choi WS; Choi SK
    Turk J Gastroenterol; 2015 Jul; 26(4):344-50. PubMed ID: 26039005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
    Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
    Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.